文献速递白血病造血干细胞移植与细胞治疗

CD7 CAR-T细胞治疗复发或难治性CD7阳性急性髓系白血病

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
PubMed 文献 · Leukemia · 2026-07-03

这项I期临床试验(NCT04599556)评估了CD7靶向CAR-T细胞疗法在复发/难治性CD7阳性急性髓系白血病(AML)患者中的安全性和疗效。客观缓解率为92.3%,MRD阴性率84.6%,但7例出现CD7阴性复发;中位随访172.5天时5例持续缓解,3年总生存率和无白血病生存率分别为34.3%和34.1%。

要点

  • CD7 CAR-T在R/R CD7阳性AML中客观缓解率92.3%,MRD阴性率84.6%。
  • 细胞因子释放综合征发生率92.9%,3-4级血细胞减少100%,病毒再激活78.6%。
  • 7例患者出现CD7阴性复发,3年总生存率34.3%。

核心结论

  • CD7 CAR-T细胞疗法在复发/难治性CD7阳性AML中显示可控的安全性和初步疗效,支持更大规模试验进一步研究。

主要发现

  • 治疗相关不良事件包括细胞因子释放综合征(92.9%)、3-4级血细胞减少(100%)、1级神经毒性(7.1%)和病毒再激活(78.6%)。
  • 客观缓解率为92.3%,MRD阴性率为84.6%。
  • 尽管初始缓解,7例患者出现CD7阴性疾病复发;中位随访172.5天时,5例患者仍处于缓解。
  • 3年总生存率和无白血病生存率分别为34.3%和34.1%。

关键数值与推荐

  • CD7在约30%的AML病例中表达。
  • 主要终点为剂量限制性毒性发生率。

临床怎么用

  • CD7 CAR-T可作为复发/难治性CD7阳性AML的潜在治疗选择,但需注意CD7阴性复发和血细胞减少等毒性管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although CAR-T cell therapy has revolutionized treatment for hematologic malignancies, its application in acute myeloid leukemia remains challenging. CD7 is expressed in approximately 30% of AML cases and represents a promising target. This phase I clinical trial (NCT04599556) evaluated CD7-targeted CAR-T cell therapy in patients with relapsed/refractory CD7-positive AML. Patients received a single infusion of autologous or donor-derived CD7 CAR-T cells using a standard 3 + 3 dose escalation design across two dose levels. The primary endpoint was the incidence of dose-limiting toxicities. Fourteen patients were enrolled. Treatment-related adverse events included cytokine release syndrome (92.9%), grade 3-4 cytopenia (100%), grade 1 neurotoxicity (7.1%), and viral reactivation (78.6%). The objective response rate was 92.3%, with an MRD-negative rate of 84.6%. Despite initial responses, seven patients relapsed with CD7-negative disease. At a median follow-up of 172.5 days, five patients remained in remission. The 3-year overall survival and leukemia-free survival rates were 34.3% and 34.1%, respectively. These initial results indicate that CD7 CAR-T cell therapy exhibits a manageable safety profile and preliminary efficacy in R/R AML patients, supporting further investigation in larger trials.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang M, Liu L, Fu S, et al. CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia. Leukemia. 2026. PMID: 42399624. doi:10.1038/s41375-026-03017-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。